The idea of transparency enjoys widespread popularity, but in practice things can become a bit murky. Take the example of the Open Payments program, which requires drug and device manufacturers to collect and report on payments they make to physicians and teaching hospitals. I spoke with a number of industry executives who all told me that while the program has a commendable goal, it’s too complicated and imposes an onerous administrative burden on companies.
Rebecca McCarty, senior vice president, chief compliance officer and associate general counsel at United Therapeutics, told me that the collection and reporting process is very hard for the company to accomplish. For example, McCarty said the company recently identified 20 records that had been classified as general payments rather than research payments. Rather than letting United Therapeutics delete the 20 records, the Centers for Medicare & Medicaid Services told the company to delete over 5,000 payment records and then re-submit them, McCarty said.
McCarty also said it’s difficult to manipulate the data contained in the Open Payments database. “The end goal of more transparency is good, but it's just not user-friendly,” McCarty said. United manufactures several hypertension medications, including Remodulin and Tyvaso, among other products, and is based in Silver Spring, Md.
I also spoke with Matthew Wetzel, a vice president and assistant general counsel at AdvaMed, a medical device trade group, who said companies face a number of hurdles when submitting their payment records to the program. He said drug and device companies have invested a lot of resources building compliance programs focused on collecting and validating data, yet the CMS still insists on doing its own internal validation, often using out-of-date data.
Manufacturers generally have the most up-to-date data on physicians, while the CMS data are often not updated for years, Wetzel said.
Read my full story here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)